TrialBlood advances2023

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.

Monzr M Al Malki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.